- Will support Sera's Transition from clinical to commercial stage company -
- Sera positioned for growth with several outcome study read-outs taking place in 2020 -
SALT LAKE CITY, April 02, 2020 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the appointment of Jay M. Moyes as Chief Financial Officer. Mr. Moyes joins Sera Prognostics as it transitions from rigorous scientific and groundbreaking clinical stage company into a rapidly growing commercial organization.
For more than two decades, Jay Moyes has served in C-level executive and board positions of both private and public companies. He currently serves as Director on the public boards of Achieve Life Sciences (NASDAQ:ACHV), BioCardia (NASDAQ: BCDA) and Puma Biotechnologies (NASDAQ:PBYI). Previous roles include board director service with Predictive Technology Group (PRED); Osiris Therapeutics (OSIR); and Integrated Diagnostics (acquired by Biodesix). Jay also served as Chief Financial Officer and Director of the publicly traded biomaterials company, Amedica Corporation (now SINTX Technologies), managing the company's IPO and listing on NASDAQ; and as Chief Financial Officer at XDx (now CareDx – CDNA).
At Myriad Genetics (MYGN) , Jay led the finance function for 14 years from the company's early private stage development beginning with 7 employees, through its successful IPO in 1996, and serving until 2007 as Chief Financial Officer during Myriad's rapid growth trajectory to become one of the world's most highly profitable molecular diagnostics companies, with over 900 employees. During that time, Moyes spearheaded the efforts in raising more than $500 million in public and private financings.
"I am thrilled to be working with Jay Moyes again, as we build Sera Prognostics into a highly successful and profitable enterprise," said Gregory C. Critchfield, MD., MS, chairman and CEO. "Jay's deep financing connections and expertise in leading biopharmaceutical, medical device and diagnostics companies, both in private and public company settings, will help Sera to achieve its vision of improving the health of mothers and babies and reducing the costs of healthcare delivery."
| "I am excited to join the talented Sera team and help accelerate the company's progress, as Greg and I successfully did together at Myriad." -Jay Moyes Click to tweet |
"Sera has achieved remarkable progress in building a world-class approach to address the immense burden of premature birth," said Jay Moyes. "The early data from outcome study reports show that Sera's PreTRM® strategy works, and that by improving the health of women and babies, the enormous personal, societal and economic consequences of prematurity can be mitigated. I am excited to join the talented Sera team and help accelerate the company's progress, as Greg and I successfully did together at Myriad."
About Clinical Outcomes Data
Sera's validated PreTRM® prediction has been taken into prospective intervention studies, where populations of pregnant women have been screened by the Sera test. Higher PreTRM®-risk pregnancies are stratified to receive earlier more proactive interventions, and important outcomes are examined in comparison to pregnancies in control groups where the test is not available.
Contacts:
Fern Lazar, Lazar FINN
[email protected]
212 867 1765
Chantal Beaudry, Lazar FINN
[email protected]
646 871 8480
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
